Oppenheimer analyst Rohit Vanjani today joined the crowd, raising ANI Pharmaceuticals (NASDAQ:ANIP) price target to $55 (from $37), while maintaining an Outperform rating on the …
In a research report released today, Oppenheimer analyst Rohit Vanjani reiterated a Perform rating on Lannett Company (NYSE:LCI), while no price target was …
In a research report sent to investors Thursday, Oppenheimer analyst Rohit Vanjani assigned an Outperform rating on ANI Pharmaceuticals (NASDAQ:ANIP) with a $37 …
In a research report issued today, Oppenheimer analyst Rohit Vanjani maintained an Outperform rating on Lannett Company (NYSE:LCI) and slightly raised his price …
In a research report issued today, Oppenheimer analyst Rohit Vanjani downgraded shares of OvaScience Inc (NASDAQ:OVAS) to Perform from an Outperform rating, as shares of OvaScience …
In a research report today, Oppenheimer analyst Rohit Vanjani reiterated an Outperform rating on Igi Laboratories (NYSE:IG) with a $10 price target, following product acquisition …
In a research report issued today, Oppenheimer analyst Rohit Vanjani reiterated an Outperform rating on Opko Health (NYSE:OPK) with a $12 price target, following yesterday’s news …
